Singapore Clinical Trial: A Phase 3, two-part, double-blind, randomized, placebo-controlled study to investigate the safety and efficacy of efimosfermin alfa injection in adult participants with compensated cirrhosis (stage F4 fibrosis) due to metabolic dysfunction-associated steatohepatitis (NEBULA-2)

Singapore, Sept. 19 -- The Health Sciences Authority received information related to the study titled 'A Phase 3, two-part, double-blind, randomized, placebo-controlled study to investigate the safety and efficacy of efimosfermin alfa injection in adult participants with compensated cirrhosis (stage F4 fibrosis) due to metabolic dysfunction-associated steatohepatitis (NEBULA-2)'. The following are the other relevant details related to the trial:

Therapeutic Area: Hepatology

Trial Centre(s): Changi General Hospital National University Hospital Singapore General Hospital

Trial Status: NA

Principal Investigator(s): Dr Rahul Kumar Dr Mark Dhinesh Muthiah Dr George Goh Boon Bee

Published by HT Digital Content Services with permission from ...